Global Intravenous Solutions (Parenteral Nutrition) Industry

  • July 2013
  • -
  • Global Industry Analysts
  • -
  • 182 pages

This report analyzes the worldwide markets for Intravenous Solutions (Parenteral Nutrition) in US$ Million.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets.

The report profiles 30 companies including many key and niche players such as Actavis, Inc., B. Braun Melsungen AG, Baxter International, Inc., Claris Lifesciences Ltd., Fresenius SE & Co. KGaA, Fresenius Kabi AG, Sino-Swed Pharmaceutical Corp. Ltd., Hospira, Inc., Otsuka Pharmaceutical Factory, Inc., Marck Biosciences Ltd., Sichuan Kelun Pharmaceutical Co., Ltd., Terumo Corporation, The Galenica Group, and Vifor Pharma.

Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

Table Of Contents




I. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation and Reporting Level I-2
Quantitative Techniques and Analytics I-3
Product Definitions and Scope of Study I-3


II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
Intravenous Solutions: A Key Aspect of the Parenteral
Nutrition Market II-1
Healthcare Economics amidst the Economic Crisis II-2
The Road Ahead II-3
Table 1: World Intravenous Solutions (Parenteral Nutrition
Market): Market Share Breakdown of Different Regional Markets
(includes corresponding Graph/Chart) II-3

Table 2: World Intravenous Solutions (Parenteral Nutrition
Market): Growth Potential Across Different Regional Markets
(includes corresponding Graph/Chart) II-4
Noteworthy Market Trends, Drivers, and Issues II-4
Non-volitional Nutritional Support Therapy - Vital for
Combating Malnutrition during Hospitalization II-4
Table 3: Daily Requirements for Adults (Male and Female) by
Nutrient Type II-5

Table 4: Energy Requirements by Age and Gender (includes
corresponding Graph/Chart) II-5

Table 5: Protein and Vitamin Requirements by Gender II-6

Table 6: Mineral Requirements by Gender and Mineral Type II-6
Rapidly Ageing Demographics to Propel Demand for Intravenous
Solutions (Parenteral Nutrition) II-6
Opportunity Indicator II-7
Table 7: Elderly Population (65+ Years) as a Percentage of
the Total Population: 2000 and 2025 (includes corresponding
Graph/Chart) II-7

Table 8: Global Population Statistics for the 65+ Age
Group: 2012 II-8
Intravenous Therapy in Outpatient Settings to Boost Market
Growth II-8
Growing Demand for Home Intravenous Therapies II-9
Rising Incidence of Chronic Diseases to Propel Growth of IV
Solutions Market II-9
Cancer Incidence Statistics II-10
Table 9: New Cancer Cases in the World by Affected Site:
2012 (in Thousands) (includes corresponding Graph/Chart) II-11

Table 10: Global Cancer Incidence by Income Group: 2012 (in
Thousands) (includes corresponding Graph/Chart) II-11

Table 11: Cancer Incidence in High Income Countries by
Site: 2012 (in Thousands) (includes corresponding
Graph/Chart) II-12

Table 12: Cancer Incidence in Upper Middle Income Countries
by Site: 2012 (in Thousands) (includes corresponding
Graph/Chart) II-13

Table 13: Cancer Incidence in Lower Middle Income Countries
by Site: 2012 (in Thousands) (includes corresponding
Graph/Chart) II-14

Table 14: Cancer Incidence in Low Income Countries by Site:
2012 (in Thousands) (includes corresponding Graph/Chart) II-15
Diabetes Mellitus Incidence Statistics II-15
Parental Nutrition Therapy Indicated for Diabetes Patients
with Non-functional Gastrointestinal Tract II-16
Table 15: Worldwide Prevalence of Diabetes Mellitus by
Region: 2012 and 2030 (includes corresponding Graph/Chart) II-17
Table 16: Prevalence of Diabetes Mellitus in Europe (2012 and
2030): Breakdown by Country and Age Group (In 000 People and %) II-18

Table 17: Prevalence of Diabetes Mellitus in South East
Asia (2012 and 2030): Breakdown by Country and Age Group (In
000 People and %) (includes corresponding Graph/Chart) II-19

Table 18: Prevalence of Diabetes Mellitus in Western Asia,
Pacific Regions (2012 and 2030): Breakdown by Country and
Age Group (In 000 People and %) II-20

Table 19: Prevalence of Diabetes Mellitus in South and
Central America (2012 and 2030): Breakdown by Country and
Age Group (In 000 People and %) II-21

Table 20: Prevalence of Diabetes Mellitus in Africa (2012 and
2030): Breakdown by Country and Age Group (In 000 People and %) II-22

Table 21: Prevalence of Diabetes Mellitus in Middle East and
North Africa (2012 and 2030): Breakdown by Country and Age
Group (In 000 People and %) II-23
Global HIV Statistics II-24
Table 22: Global Summary of the AIDS Epidemic in 2011 II-24

Table 23: Global HIV Statistics for the Year 2010 II-24
Parenteral Nutrition in Select Gastrointestinal Disorders II-24
Intravenous Infusion Technology to Influence the Future
Growth Prospects II-25
Pre-mixed IV Solutions: A Step towards Safer Medication
Practices II-25
The Need for Low-Cost Solutions II-26
Continuous Supply of Raw Material: Crucial for Production of
IV Solutions II-26
Rising Popularity of Intravenous Vitamin C for Cancer Treatment II-26
Increasing Demand for Peripheral Intravenous Nutrition II-27
Iron Replacement Therapies: An Opportunity Area for
Intravenous Solutions (Parenteral Nutrition) II-27
Issues II-27
Rising Preference for Enteral Nutrition: A Threat to
Parenteral Nutrition Market II-27
Cost Containment Continues to Pressurize Product Pricing II-28
Infection Control: A Prime Concern in IV Therapy II-29
Complacency of Hospitals and Worker/Patient Safety: A Key Issue II-29
Competition In the Parenteral Nutrition Market II-30
Table 24: Leading Players in the Global Parenteral Nutrition
Market (2012): Percentage Share Breakdown of Value Sales for
Baxter, Fresenius Kabi, B. Braun Melsungen, Hospira and
Others (includes corresponding Graph/Chart) II-30

2. INTRAVENOUS SOLUTIONS II-32
Intravenous Therapy II-32
Defining Intravenous Solutions II-32
Tonicity and Osmolality II-33
Production of IV Solutions II-33
Types of IV Solutions II-33
Colloid Solutions II-33
Crystalloid Solutions II-33
Properties of IV Solution Type Based on Concentration II-34
Isotonic Crystalloids II-34
Hypertonic Crystalloids II-35
Hypotonic Crystalloids II-35
Commonly Used Crystalloid Solutions II-35
Saline Solution II-35
Normal Saline II-36
Half-Normal Saline II-36
Quarter-Normal Saline II-36
Hypertonic Saline II-36
Dextrose II-36
Saline with Additional Ingredients II-36
Intravenous Sugar Solution II-36
Dextrose Solutions or D5W II-37
Other Types II-37
Pre-mixed IV Solutions II-37
Large and Small Volume Intravenous Solutions II-37
Devices Used in IV Solutions Administration II-38
Types of Intravenous Access Devices II-38
Peripheral Cannula II-38
Central IV Lines II-39
Implantable Ports II-39
Tunneled Lines II-39
Peripherally Inserted Central Catheter (PICC) II-39
IV Fluid Packaging II-40
Possible Risks in Intravenous Therapy II-40
Embolism II-40
Electrolyte Imbalance II-40
Extravasation/Infiltration II-40
Phlebitis II-41
Infection II-41

3. PARENTERAL NUTRITION - AN OVERVIEW II-42
An Introduction II-42
Parenteral Nutrition II-43
Sources of Parenteral Solutions II-44
Routes of Administration II-44
Types of Parenteral Nutrition Solutions II-45
Total Parenteral Nutrition (TPN) II-45
Daily Requirements for Total Parenteral Nutrition (TPN) in
Adults II-45
Daily Recommended Parenteral Nutritional Intakes for Newborns II-46
Partial Parenteral Nutrition (PPN) II-47
Home Parenteral Nutrition II-47
Parenteral Nutrition Formulations II-47
Standard Solutions II-47
Non-Standard Solutions II-48
Classification of Parenteral Nutrition by Type of Nutrients II-48
Amino Acids II-48
Carbohydrates II-48
Lipids II-49
Minerals and Electrolytes II-49
Micronutrients II-50
Vitamins II-50
Trace Elements II-51
Large and Small Volume Parenteral Solutions II-51
Large Volume Parenteral (LVP) Solutions II-51
Small Volume Parenteral (SVP) Solutions II-52
IV Fat Emulsions - Enabling Maintenance of Bodyweight II-52
Regulatory Prerequisites II-52

4. PRODUCT LAUNCHES II-53
FDA Clears Fresenius Kabi for Emergency Import of
Injectionable TPN Drugs II-53
Marck Biosciences Receives MCC Approval for Pharma Products
(South Africa) II-53
EC Grants Clearance for Ferumoxytol IV Iron Therapy II-53
Claris Receives USFDA Approval for Marketing Products in the
US (US) II-53
Taiho to Roll Out Aloxi® 0.75mg I.V Infusion Bag II-54
Baxter International Launches OLIMEL Emulsion II-54
Baxter International Launches NUMETA in Europe II-54
B. Braun Rolls Out NuTRIflex® Omega II-54
Episys Launches New Version of Ultimate Parenteral Nutrition
Module II-55

5. RECENT INDUSTRY ACTIVITY II-56
Hospira Recalls IV Electrolyte Solution II-56
Becton, Dickinson and Company Takes over Cato Software Solutions II-56
Otsuka Pharmaceutical Factory Forms a JV with Claris
Lifesciences and Mitsui II-56
B. Braun Establishes Pharmaceutical Plant in Fogelsville, US II-56
Baxter International Completes Acquisition of SIGMA
International (US) II-57
Aperture Health Takes Over Triad Therapeutics (US) II-57
Children's Hospitals and Clinics of Minnesota Deploys Cerner
CareAwareiBusTM of CareFusion II-57
Baxter Initiates Class I Recall of Automix Compounder II-58
Tosho Acquires Minority Interest in Health Robotics (Italy) II-58
Baxter International Acquires Baxa II-59
Baxter Healthcare Acquires Prism Pharmaceuticals II-59
Galenica Takes Over ViforUriachPharma II-59
Fresenius Kabi Establishes Manufacturing Plant in Vietnam II-60
Grifols to Set Up Form-Fill-Seal Production Lines for
Parenteral Solutions II-60
IVAL Pharma to Establish Pharmaceutical Plant in Uzbekistan II-60
National Medical Solutions to Establish Medical Facility in
Abu Dhabi II-60
Baxter Healthcare Obtains USFDA Approval for AVIVA Intravenous
Solutions (US) II-61
FMC and ViforPharma Team Up to Form Vifor Fresenius II-61
Marck Biosciences Acquire Injectible Facility of Ravish Infusion II-62
Lijun Forms JV with TonghuaDongbao Pharmaceuticals II-62
ADIH and Bram S.p.A. Ink Agreement for Wellpharma’s IV
Production Facility II-62
Hospira Signs Multi-product Agreements with MedAssets II-62
Hospira Enters into Agreements with Novation II-62
Mission Health System Commences Production of RIVA-produced IV
Solution II-63
Mission Health Systems Selects Automation Solution from IHS II-63
Applied Research Associates Bags Contract for Packaged
Intravenous Fluids II-63
Hospira Announces Migration to Non-DEHP Based IV
Administration Units II-63

6. FOCUS ON SELECT GLOBAL PLAYERS II-64
Actavis, Inc. (US) II-64
B. Braun Melsungen AG (Germany) II-64
Baxter International, Inc. (US) II-65
Claris Lifesciences Ltd. (India) II-66
Fresenius SE and Co. KGaA (Germany) II-66
Fresenius KABI AG (Germany) II-66
Sino-Swed Pharmaceutical Corp. Ltd. (China) II-67
Hospira, Inc. (US) II-67
Otsuka Pharmaceutical Factory, Inc. II-68
Marck Biosciences Ltd. (India) II-68
Sichuan Kelun Pharmaceutical Co., Ltd. (China) II-68
Terumo Corporation (Japan) II-69
The Galenica Group (Switzerland) II-69
Vifor Pharma (Switzerland) II-69

7. GLOBAL MARKET PERSPECTIVE II-71
Table 25: World Recent Past, Current and Future Analysis for
Intravenous Solutions (Parenteral Nutrition) by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific, Latin
America, and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for the Years 2010 through
2018 (includes corresponding Graph/Chart) II-71

Table 26: World Historic Review for Intravenous Solutions
(Parenteral Nutrition) by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific, Latin America, and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for the Years 2004 through 2009 (includes
corresponding Graph/Chart) II-72

Table 27: World 15-Year Perspective for Intravenous Solutions
(Parenteral Nutrition) by Geographic Region - Percentage
Breakdown of Value Sales for US, Canada, Japan, Europe,
Asia-Pacific, Latin America, and Rest of World Markets for the
Years 2004, 2013 and 2018 (includes corresponding Graph/Chart) II-73


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Table 28: The US Population by Age Group and Gender (2011)
(includes corresponding Graph/Chart) III-1
Impact of Patient Protection and Affordable Care Act (2010)
on the IV Solutions Market III-2
Increasing Usage of Intravenous Iron in the US III-2
Cancer Trends in the US III-3
Table 29: New Cancer Cases in the US by Gender and Affected
Site: 2012 III-3

Table 30: New Cancer Cases in Males in US by Leading Site:
2012 (includes corresponding Graph/Chart) III-4
Prevalence of Diabetes Mellitus in North America III-4
Table 31: Prevalence of Diabetes Mellitus in North America:
2012 (includes corresponding Graph/Chart) III-5

Table 32: North America Incidence of Type 1 Diabetes in
Children: 2012 (includes corresponding Graph/Chart) III-5
Strategic Corporate Developments III-6
Focus on Select Major Players III-9
B.Market Analytics III-12
Table 33: The US Recent Past, Current and Future Analysis
for Intravenous Solutions (Parenteral Nutrition) Analyzed
with Annual Sales Figures in US$ Million for the Years 2010
through 2018 (includes corresponding Graph/Chart) III-12

Table 34: The US Historic Review for Intravenous Solutions
(Parenteral Nutrition) Analyzed with Annual Sales Figures in
US$ Million for the Years 2004 through 2009 (includes
corresponding Graph/Chart) III-12

2. CANADA III-13
A.Market Analysis III-13
Cancer Statistics in Canada III-13
Table 35: New Cancer Cases in Canada by Gender and Affected
Site: 2012 (includes corresponding Graph/Chart) III-13

Table 36: New Cancer Cases in Canada by Province: 2012
(includes corresponding Graph/Chart) III-14

Table 37: New Cancer Cases in Canada by Age Group: 2012
(includes corresponding Graph/Chart) III-15
Diabetes Statistics in Canada III-15
Table 38: Prevalence of Diabetes Mellitus in Canada: 2012
(includes corresponding Graph/Chart) III-15
Product Launches III-16
B.Market Analytics III-17
Table 39: Canadian Recent Past, Current and Future Analysis
for Intravenous Solutions (Parenteral Nutrition) Analyzed
with Annual Sales Figures in US$ Million for the Years 2010
through 2018 (includes corresponding Graph/Chart) III-17

Table 40: Canadian Historic Review for Intravenous Solutions
(Parenteral Nutrition) Analyzed with Annual Sales Figures in
US$ Million for the Years 2004 through 2009 (includes
corresponding Graph/Chart) III-18

3. JAPAN III-19
A.Market Analysis III-19
Table 41: Prevalence of Diabetes Mellitus in Japan: 2012 and
2030 (includes corresponding Graph/Chart) III-19
Strategic Corporate Developments III-19
Focus on Select Players III-20
B.Market Analytics III-21
Table 42: Japanese Recent Past, Current and Future Analysis
for Intravenous Solutions (Parenteral Nutrition) Analyzed
with Annual Sales Figures in US$ Million for the Years 2010
through 2018 (includes corresponding Graph/Chart) III-21

Table 43: Japanese Historic Review for Intravenous Solutions
(Parenteral Nutrition) Analyzed with Annual Sales Figures in
US$ Million for the Years 2004 through 2009 (includes
corresponding Graph/Chart) III-22

4. EUROPE III-23
A.Market Analysis III-23
Debt Crisis in Europe Affects Healthcare Industry III-23
Healthcare System . in State of Transition? III-23
Age Statistics III-24
Table 44: Europe Population Age Structure as a Percentage
of Total Population for the Year 2011 III-24
Cancer Trends III-25
Table 45: Cancer Incidence in Europe by Site: 2012 (in
Thousands) (includes corresponding Graph/Chart) III-25
Prevalence of Diabetes Mellitus in Europe III-26
Table 46: Prevalence of Diabetes Mellitus in Europe (2012 and
2030): Breakdown by Country and Age Group (In 000 People and %) III-26
Strategic Corporate Initiatives III-27
B.Market Analytics III-29
Table 47: European Recent Past, Current and Future Analysis
for Intravenous Solutions (Parenteral Nutrition) by
Geographic Region - France, Germany, Italy, UK, Spain,
Russia, and Rest of Europe Markets Independently Analyzed
with Annual Sales Figures in US$ Million for the Years 2010
through 2018 (includes corresponding Graph/Chart) III-29

Table 48: European Historic Review for Intravenous Solutions
(Parenteral Nutrition) by Geographic Region - France,
Germany, Italy, UK, Spain, Russia, and Rest of Europe
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for the Years 2004 through 2009 (includes
corresponding Graph/Chart) III-30

Table 49: European 15-Year Perspective for Intravenous
Solutions (Parenteral Nutrition) by Geographic Region -
Percentage Breakdown of Value Sales for France, Germany,
Italy, UK, Spain, Russia, and Rest of Europe Markets for the
Years 2004, 2013 and 2018 (includes corresponding
Graph/Chart) III-31

4a. FRANCE III-32
Market Analysis III-32
Table 50: French Recent Past, Current and Future Analysis
for Intravenous Solutions (Parenteral Nutrition) Analyzed
with Annual Sales Figures in US$ Million for the Years 2010
through 2018 (includes corresponding Graph/Chart) III-32

Table 51: French Historic Review for Intravenous Solutions
(Parenteral Nutrition) Analyzed with Annual Sales Figures in
US$ Million for the Years 2004 through 2009 (includes
corresponding Graph/Chart) III-33

4b. GERMANY III-34
A.Market Analysis III-34
Select Key Players III-34
B.Market Analytics III-36
Table 52: German Recent Past, Current and Future Analysis
for Intravenous Solutions (Parenteral Nutrition) Analyzed
with Annual Sales Figures in US$ Million for the Years 2010
through 2018 (includes corresponding Graph/Chart) III-36

Table 53: German Historic Review for Intravenous Solutions
(Parenteral Nutrition) Analyzed with Annual Sales Figures in
US$ Million for the Years 2004 through 2009 (includes
corresponding Graph/Chart) III-37

4c. ITALY III-38
Market Analysis III-38
Table 54: Italian Recent Past, Current and Future Analysis
for Intravenous Solutions (Parenteral Nutrition) Analyzed
with Annual Sales Figures in US$ Million for the Years 2010
through 2018 (includes corresponding Graph/Chart) III-38

Table 55: Italian Historic Review for Intravenous Solutions
(Parenteral Nutrition) Analyzed with Annual Sales Figures in
US$ Million for the Years 2004 through 2009 (includes
corresponding Graph/Chart) III-39

4d. THE UNITED KINGDOM III-40
Market Analysis III-40
Table 56: The UK Recent Past, Current and Future Analysis
for Intravenous Solutions (Parenteral Nutrition) Analyzed
with Annual Sales Figures in US$ Million for the Years 2010
through 2018 (includes corresponding Graph/Chart) III-40

Table 57: The UK Historic Review for Intravenous Solutions
(Parenteral Nutrition) Analyzed with Annual Sales Figures in
US$ Million for the Years 2004 through 2009 (includes
corresponding Graph/Chart) III-41

4e. SPAIN III-42
A.Market Analysis III-42
Grifols International S.A. - A Key Player III-42
B.Market Analytics III-43
Table 58: Spanish Recent Past, Current and Future Analysis
for Intravenous Solutions (Parenteral Nutrition) Analyzed
with Annual Sales Figures in US$ Million for the Years 2010
through 2018 (includes corresponding Graph/Chart) III-43

Table 59: Spanish Historic Review for Intravenous Solutions
(Parenteral Nutrition) Analyzed with Annual Sales Figures in
US$ Million for the Years 2004 through 2009 (includes
corresponding Graph/Chart) III-44

4f. RUSSIA III-45
Market Analysis III-45
Table 60: Russian Recent Past, Current and Future Analysis
for Intravenous Solutions (Parenteral Nutrition) Analyzed
with Annual Sales Figures in US$ Million for the Years 2010
through 2018 (includes corresponding Graph/Chart) III-45

Table 61: Russian Historic Review for Intravenous Solutions
(Parenteral Nutrition) Analyzed with Annual Sales Figures in
US$ Million for the Years 2004 through 2009 (includes
corresponding Graph/Chart) III-46

4g. REST OF EUROPE III-47
A.Market Analysis III-47
Focus on Select Key Players III-47
B.Market Analytics III-48
Table 62: Rest of European Recent Past, Current and Future
Analysis for Intravenous Solutions (Parenteral Nutrition)
Analyzed with Annual Sales Figures in US$ Million for the
Years 2010 through 2018 (includes corresponding Graph/Chart) III-48

Table 63: Rest of European Historic Review for Intravenous
Solutions (Parenteral Nutrition) Analyzed with Annual Sales
Figures in US$ Million for the Years 2004 through 2009
(includes corresponding Graph/Chart) III-49

5. ASIA-PACIFIC III-50
A.Market Analysis III-50
Cancer Trends in Asia-Pacific III-50
Table 64: Cancer Incidence in Asia-Oceania by Site: 2011
(in Thousands) (includes corresponding Graph/Chart) III-50
Diabetes Statistics III-51
Table 65: Prevalence of Diabetes Mellitus in South East
Asia (2012 and 2030): Breakdown by Country and Age Group (In
000 People and %) (includes corresponding Graph/Chart) III-51

Table 66: Prevalence of Diabetes Mellitus in Western Asia,
Pacific Regions (2012 and 2030): Breakdown by Country and Age
Group (In 000 People and %) III-52

Table 67: Incidence of Type 1 Diabetes in Children by
Select Countries in the Western Pacific: 2012 (includes
corresponding Graph/Chart) III-53
B.Market Analytics III-54
Table 68: Asia-Pacific Recent Past, Current and Future
Analysis for Intravenous Solutions (Parenteral Nutrition) by
Geographic Region - China, Australia, and Rest of
Asia-Pacific Markets Independently Analyzed with Annual
Sales Figures in US$ Million for the Years 2010 through 2018
(includes corresponding Graph/Chart) III-54

Table 69: Asia-Pacific Historic Review for Intravenous
Solutions (Parenteral Nutrition) by Geographic Region -
China, Australia, and Rest of Asia-Pacific Markets
Independently Analyzed with Annual Sales Figures in US$
Million for the Years 2004 through 2009 (includes
corresponding Graph/Chart) III-55

Table 70: Asia-Pacific 15-Year Perspective for Intravenous
Solutions (Parenteral Nutrition) by Geographic Region -
Percentage Breakdown of Value Sales for China, Australia,
and Rest of Asia-Pacific Markets for the Years 2004, 2013
and 2018 (includes corresponding Graph/Chart) III-56

5a. CHINA III-57
A.Market Analysis III-57
Table 71: Chinese Intravenous Solutions Products Packaging
(2012): Percentage Share Breakdown of Volume Sales for Glass
Bottles, and Plastic Bottles and Non-PVC Soft Bags (includes
corresponding Graph/Chart) III-57
Strategic Corporate Development III-57
Focus on Select Key Players III-58
B.Market Analytics III-59
Table 72: Chinese Recent Past, Current and Future Analysis
for Intravenous Solutions (Parenteral Nutrition) Analyzed
with Annual Sales Figures in US$ Million for the Years 2010
through 2018 (includes corresponding Graph/Chart) III-59

Table 73: Chinese Historic Review for Intravenous Solutions
(Parenteral Nutrition) Analyzed with Annual Sales Figures in
US$ Million for the Years 2004 through 2009 (includes
corresponding Graph/Chart) III-60

5b. AUSTRALIA III-61
Market Analysis III-61
Table 74: Australian Recent Past, Current and Future
Analysis for Intravenous Solutions (Parenteral Nutrition)
Analyzed with Annual Sales Figures in US$ Million for the
Years 2010 through 2018 (includes corresponding Graph/Chart) III-61

Table 75: Australian Historic Review for Intravenous
Solutions (Parenteral Nutrition) Analyzed with Annual Sales
Figures in US$ Million for the Years 2004 through 2009
(includes corresponding Graph/Chart) III-62

5c. REST OF ASIA-PACIFIC III-63
A.Market Analysis III-63
An Overview of the IV Solutions Market in India III-63
Strategic Corporate Developments III-63
Focus on Select Key Players III-64
B.Market Analytics III-67
Table 76: Rest of Asia-Pacific Recent Past, Current and
Future Analysis for Intravenous Solutions (Parenteral
Nutrition) Analyzed with Annual Sales Figures in US$ Million
for the Years 2010 through 2018 (includes corresponding
Graph/Chart) III-67

Table 77: Rest of Asia-Pacific Historic Review for
Intravenous Solutions (Parenteral Nutrition) Analyzed with
Annual Sales Figures in US$ Million for the Years 2004
through 2009 (includes corresponding Graph/Chart) III-68

6. LATIN AMERICA III-69
Market Analysis III-69
Table 78: Latin American Recent Past, Current and Future
Analysis for Intravenous Solutions (Parenteral Nutrition)
Analyzed with Annual Sales Figures in US$ Million for the
Years 2010 through 2018 (includes corresponding Graph/Chart) III-69

Table 79: Latin American Historic Review for Intravenous
Solutions (Parenteral Nutrition) Analyzed with Annual Sales
Figures in US$ Million for the Years 2004 through 2009
(includes corresponding Graph/Chart) III-70

7. REST OF WORLD III-71
A.Market Analysis III-71
The Middle East III-71
Uganda III-71
Prevalence Statistics of Diabetes Mellitus III-72
Table 80: Prevalence of Diabetes Mellitus in Africa (2012 and
2030): Breakdown by Country and Age Group (In 000 People and %) III-72

Table 81: Prevalence of Diabetes Mellitus in The Middle
East and North Africa (2012 and 2030): Breakdown by Country and
Age Group (In 000 People and %) III-73
Product Launch III-73
B.Market Analytics III-74
Table 82: Rest of World Recent Past, Current and Future
Analysis for Intravenous Solutions (Parenteral Nutrition)
Analyzed with Annual Sales Figures in US$ Million for the
Years 2010 through 2018 (includes corresponding Graph/Chart) III-74

Table 83: Rest of World Historic Review for Intravenous
Solutions (Parenteral Nutrition) Analyzed with Annual Sales
Figures in US$ Million for the Years 2004 through 2009
(includes corresponding Graph/Chart) III-75


IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 30 (including Divisions/Subsidiaries - 36)

The United States (10)
Japan (4)
Europe (11)
- France (1)
- Germany (3)
- The United Kingdom (1)
- Italy (1)
- Spain (1)
- Rest of Europe (4)
Asia-Pacific (Excluding Japan) (10)
Africa (1)

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Analysis of the Global Infectious Disease Diagnostics Market

Analysis of the Global Infectious Disease Diagnostics Market

  • $ 10 000
  • Industry report
  • September 2014
  • by Frost & Sullivan

Molecular Methods Present Significant Opportunities This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast ...

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 Summary Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled ...

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • July 2014
  • by GBI Research

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation Summary Exceptionally Large and Innovative Pipeline The breast cancer pipeline is the largest in the pharmaceutical ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

6 Companies

Company Profiles

SYNTHES Inc.

Switzerland

Biosense Webster Inc.

United States

Synthes Inc.

United States

Johnson and Johnson

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.